340B Patient Definition Gets Much-Needed Update In Omnibus Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
HRSA's long-awaited comprehensive guidance clarifies numerous program policies and procedures to help ensure integrity of the drug discount program.
You may also be interested in...
340B Freeze: 'Mega-Guidance' Withdrawn; Clarity On Program Boundaries Delayed Again
Long-delayed effort to define key boundaries for 340B drug discount program is on hold once again – and it may now take legislation to enable HRSA to move forward with plans to better define who is eligible for the discount.
340B “Mega-Guidance” Delayed To December (Or Beyond)
HRSA official stresses importance “good faith” by manufacturers and purchasers to assure program integrity while key definitions remain in limbo.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.